The use of darbepoetin alfa to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS) was evaluated in a phase 3 trial. Eligible patients had low/intermediate-1 risk MDS, hemoglobin ...
Amgen recently announced the launch of the darbepoetin alfa (Aranesp)-prefilled SureClick autoinjector for patients with chemotherapy-induced anemia and anemia associated with chronic kidney disease ...
THOUSAND OAKS, California-The US Food and Drug Administration has approved Amgen’s Aranesp (darbepoetin alfa) for the treatment of chemotherapy-induced anemia in patients with nonmyeloid malignancies.
This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...
Cipla collaborates with Hetero to launch its second biosimilar drug 'Darbepoetin alfa' ~Patients with chronic kidney disease and anaemia set to gain~ India, Mumbai, 19th June 2014: Cipla, a global ...
Purpose: The cost of darbepoetin alfa versus that of epoetin alfa in a hospital setting was studied. Methods: The study was an observational, retrospective review of the hospitalwide use of ...
A new study published in the Journal of Perinatology is helping premature babies avoid blood transfusions, thanks to new research and collaboration between researchers at Intermountain Health in Salt ...
The US Food and Drug Administration (FDA) has approved epoetin and darbepoetin for chemotherapy-induced anemia (CIA). Approved epoetin and darbepoetin dosing schedules were three times per week and ...
LOS ANGELES (Reuters) - Amgen Inc. said on Monday that 48.5 percent of cancer patients not undergoing chemotherapy or radiation who received its anemia drug Aranesp in a clinical trial died compared ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Darbepoetin alfa did not decrease the risk for death, ...
The novel erythropoetic protein darbepoetin alfa exhibits enhanced biological activity and increased serum half-life compared with other erythropoetic agents used to treat chemotherapy-related anemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results